Lead Sponsor

Novartis Pharmaceuticals

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

•Patients 18 years of age or older
•Confirmed diagnosis of Multiple Myeloma
•Stable renal function defined as two serum creatinine determinations of \< 3 mg/dL
•Calculated creatinine clearance of greater than or equal to 30 mL/min
•ECOG Performance Status of 0 or 1
•Life expectancy of greater than or equal to 9 months
•If the patient is of child-bearing potential, a negative pregnancy test is required at screening, while postmenopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential.
•Ability to comply with trial requirements and give informed consent.

•IV Bisphosphonate therapy for more than 3 years.
•Patients with a diagnosis of amyloidosis.
•Known hypersensitivity to zoledronic acid or other bisphosphonates
•Pregnant patients or lactating patients.
•Women of childbearing potential not on a medically recognized form of contraception
•Patients with uncontrolled cardiovascular disease, hypertension, and Type 2 diabetes mellitus.

Related studies

NCT07249528 · Non-hodgkin Lymphoma, Multiple Myeloma

NCT06215118 · Multiple Myeloma

NCT06679101 · Multiple Myeloma, Newly Diagnosed Multiple Myeloma

NCT05969860 · Advanced Anal Carcinoma, Advanced Biliary Tract Carcinoma, and more

NCT06383143 · AL Amyloidosis, Smoldering Multiple Myeloma, and more

A Multiple Myeloma Trial in Patients With Bone Metastases